Overview

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

This is a study to determine the safety of CDX-0159 in patients with Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria.

Phase:

Phase 1

Details

Lead Sponsor:

Celldex Therapeutics